The Data Could Not Be Verified. The Drug Still Failed the Trials.

In May 2020, The Lancet published a study claiming to cover more than 96,000 COVID-19 patients. Within two weeks it was retracted, because the data could not be checked. The scandal was real, the scam was set and the lie was told.

That charge comes from Liz Churchill (@liz_churchill10), who posted it on X Wednesday evening, beside a screenshot of a ZeroHedge item on the 2020 Surgisphere affair. “They invented 96,000 patients that never existed…got The Lancet to publish it…and used it to kill a cheap drug overnight…so they could get Emergency Use Authorization for the ‘Covid Vaccine’,” she wrote.

On May 22, 2020, The Lancet published a multinational registry analysis by Mandeep Mehra and colleagues, including Sapan Desai of Surgisphere. It claimed to include 96,032 patients from 671 hospitals on six continents, and reported that hydroxychloroquine or chloroquine was associated with higher in-hospital mortality and ventricular arrhythmias. The World Health Organization soon paused the hydroxychloroquine arm of its Solidarity trial. Other trials paused too.

The data did not survive scrutiny. A Guardian investigation found that Surgisphere, a little-known Chicago company with a handful of employees, could not adequately explain a hospital database of that scale, and it identified anomalies in the figures. Independent reviewers were not given the full dataset, client contracts, and audit report. On June 4, three co-authors said they could no longer vouch for the primary data and asked the journal to retract the paper. The New England Journal of Medicine retracted a related Surgisphere paper the same day. Richard Horton, the journal’s editor, told The Guardian it was “a shocking example of research misconduct in the middle of a global health emergency.”

That failure did real damage: trials were interrupted, and trust in pandemic research took a blow. The rest of the claim does not follow. The U.S. Food and Drug Administration had authorized chloroquine and hydroxychloroquine for certain hospitalized patients on March 28, 2020. It revoked that emergency use authorization on June 15, not on the strength of the retracted paper, but after reviewing randomized evidence. The United Kingdom’s RECOVERY trial reported on June 5 that among 1,542 patients assigned hydroxychloroquine and 3,132 assigned usual care, 28-day mortality was 25.7 percent versus 23.5 percent, with no meaningful benefit. The FDA cited results from a large randomized trial in hospitalized patients and concluded the drugs were unlikely to be effective for the authorized use.

Later large randomized trials reached the same conclusion in hospital care. WHO stopped Solidarity’s hydroxychloroquine arm on June 17 after its own data and RECOVERY showed no mortality benefit, and published those results in October. The FDA’s first COVID-19 vaccine emergency use authorization, for the Pfizer-BioNTech shot, came on December 11, 2020, nearly six months later. By then the agency had already approved remdesivir as a COVID-19 treatment. No public evidence has shown that the Surgisphere papers were produced to clear that authorization.

The scandal is serious enough without the extra story. A database that could not be audited reached two leading journals, moved global trial policy, and was retracted only after scientists and journalists forced the issue. That is documented. It is not proof the paper was written to kill a cheap drug so a vaccine could be authorized. Hydroxychloroquine’s use in hospitalized COVID-19 patients was settled by randomized trials, not by a study The Lancet could not defend.

A longer recent account is Maryanne Demasi’s November 15 Brownstone Institute essay, “The Real-World Data Dilemma.”

Original post: Liz Churchill on X

Leave a Comment